HCA Healthcare Reports First Quarter 2023 Results
HCA Healthcare, Inc. (NYSE:HCA), today announced financial and operating results for the first quarter ended March 31, 2023. Key first quarter metrics (all percentage changes compare 1Q 2023 to 1Q 2022 unless otherwise noted): “Once again this quarter, our colleagues demonstrated a…
HCA Healthcare Appoints Jyric Sims President of Company’s West Florida Division
HCA Healthcare, Inc. (NYSE: HCA) today announced Jyric Sims, Ph.D., will become president of the company’s West Florida Division, effective June 12. Jyric Sims, Ph.D. (Photo: Business Wire) Sims, who currently is CEO of HCA Healthcare’s Medical City Plano and Medical…
Merck to Participate in Bank of America Securities 2023 Healthcare Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, is scheduled to participate in a fireside chat at the Bank of America Securities 2023…
Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC), by a vote of 11 to 1 with one abstention, supported FDA…
Merck Announces First-Quarter 2023 Financial Results
RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2023. “Inspired by our commitment to bring bold science forward to address critical unmet patient needs, we…
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination With KEYTRUDA® (pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the first presentation of detailed results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial…
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-966 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (gemcitabine and cisplatin) for the first-line…
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (“Prometheus”) (Nasdaq: RXDX) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire…
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy,…
Merck Named One of Fortune’s 2023 100 Best Companies to Work For®
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has earned a place on the Fortune 100 Best Companies to Work For list for the second time in the past three years. The company also made the…
Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase…
mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA® (pembrolizumab), Receives PRIME Scheme Designation from the European Medicines Agency for Adjuvant Treatment of Patients with High-Risk Stage III/IV Melanoma Following Complete Resection
CAMBRIDGE, MA and RAHWAY, N.J., April 6, 2023 – Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational…